Magnetic resonance imaging (MRI) has become the global standard for diagnosing prostate cancer over the last five years. However, its widespread adoption has faced challenges due to limited resources and growing demand.
Two types of MRI are used for prostate cancer detection: multiparametric MRI (mpMRI), which includes T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences; and biparametric MRI (bpMRI), which excludes the contrast-enhanced sequences.
Skipping the contrast step can significantly reduce MRI time to 15–20 minutes. It also lowers costs because fewer medical staff are needed to manage potential allergic reactions.
A recent study published in JAMA examined whether biparametric MRI is as effective as the full multiparametric MRI in diagnosing prostate cancer. The PRIME Diagnostic Clinical Trial included 490 biopsy-naive men in a multicenter, prospective study.
Researchers found that bpMRI was noninferior to mpMRI in detecting clinically significant prostate cancer (Gleason Grade Group 2 or higher). The difference in detection was only −0.4 percentage points.
The study suggests that, when image quality is sufficient, an abbreviated bpMRI—with or without targeted biopsy—could become a new standard for prostate cancer diagnosis.
A JAMA editorial emphasized that bpMRI could improve patient experience and increase access to care by reducing time, cost, and invasiveness. However, it also warned that variability in image quality across centers could affect results and requires careful implementation in clinical practice.
These findings may help streamline prostate disease diagnosis while maintaining accuracy, potentially benefiting patients and healthcare systems alike.
Related topics
Prostate Max: A Natural Supplement for Prostate Health and Male Vitality
